EcoDrugPlus

60s Ribosomal Protein L12-Like

Ensembl ID : ENSSFOG00015031530
Gene Symbol: LOC108937988
3 Cross references
423 Possible Orthologues:

60s Ribosomal Protein L18a-Like

Ensembl ID : ENSSFOG00015011612
Gene Symbol: LOC108942560
3 Cross references
362 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSSFOG00015023481
Gene Symbol: LOC108941691
3 Cross references
369 Possible Orthologues:

60s Ribosomal Protein L19-Like

Ensembl ID : ENSSFOG00015011448
Gene Symbol: LOC108919493
3 Cross references
368 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSSFOG00015030571
Gene Symbol: LOC108933481
3 Cross references
266 Possible Orthologues:

60s Ribosomal Protein L22-Like

Ensembl ID : ENSSFOG00015006425
Gene Symbol: LOC108918319
3 Cross references
138 Possible Orthologues:

60s Ribosomal Protein L28-Like

Ensembl ID : ENSSFOG00015025883
Gene Symbol: LOC108933430
3 Cross references
283 Possible Orthologues:

60s Ribosomal Protein L30-Like

Ensembl ID : ENSSFOG00015002915
Gene Symbol: LOC108919215
2 Cross references
350 Possible Orthologues:

72 Kda Type Iv Collagenase-Like

Ensembl ID : ENSSFOG00015001040
Gene Symbol: LOC108926353
3 Cross references
207 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSFOG00015023274
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSSFOG00015012538
Gene Symbol: ABL1
3 Cross references
200 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSSFOG00015011289
Gene Symbol: ABL1
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).